HULUWA(SH:605199) Huan Qiu Wang·2025-12-09 01:27Group 1 - The flu activity in China is on the rise, with a peak expected between mid-December and early January, leading to increased demand for antiviral and symptomatic treatment drugs, especially among children [1] - Bank securities report indicates that antiviral drugs are the main treatment method, with good expected efficacy; various traditional Chinese medicines and antipyretics are also available to alleviate symptoms during the illness [1] - Data from Meituan shows that since November, the overall order volume for specific flu medications has increased by over 100%, with orders for Oseltamivir granules rising by over 85% and for Baloxavir increasing by over 110% [1] Group 2 - Hainan Huhuwawa Pharmaceutical Group's Oseltamivir products have performed well, with capsules approved for production and stable market supply for the prevention and treatment of influenza A and B [3] - The company has developed a dry suspension that received drug registration certification in September, addressing dosage challenges for young children aged two and above [3] - The core product, Pediatric Lung Heat Cough and Asthma Granules, has been included in national treatment guidelines and health insurance directories, enhancing its market presence [3] Group 3 - Huhuwawa Pharmaceutical emphasizes research and innovation as a core driver for development, continuously enhancing R&D efforts in the pediatric medication sector [4] - The company has increased investment in R&D for pediatric drugs, with ongoing projects targeting infectious diseases, functional dyspepsia, allergic diseases, and adenoid hypertrophy [4]